Silexion is focusing on silencing cancer-driving proteins before they are produced, particularly mutated KRAS proteins which are prevalent in various cancers.
Their approach involves using siRNA technology to silence the expression of mutated KRAS proteins at the outset, offering a potentially safer and more durable method.
Silexion's Phase 2 Proof-of-Concept (POC) showed promising results in a clinical trial for locally advanced pancreatic cancer, indicating a potential improvement in overall survival.
Mutated KRAS Proteins
92% prevalence in pancreatic cancer, 49% in colorectal cancer, and 35% in non-small-cell-non-squamous lung cancer.
SiRNA Technology
Targets mutated KRAS proteins at the gene expression level, potentially offering a safer approach compared to conventional methods.
Phase 2 Clinical Trial
Demonstrated a strong trend for 9.3 months improvement in overall survival with siG12DLoder + standard of care (SoC) chemotherapy.
- Silexion's focus on gene expression silencing presents a novel approach in cancer treatment, potentially leading to more effective and targeted therapies.
- The successful preclinical results of SIL204 in targeting multiple cancer types show promise for future clinical development and market penetration.
Silexion's innovative approach to silencing oncogenes at the gene expression level could revolutionize cancer treatment by addressing the limitations of current therapies targeting mutated KRAS proteins.